Synta names new CEO
This article was originally published in Scrip
Executive Summary
Synta Pharmaceuticals, a biopharmaceutical company developing small-molecule drugs for severe medical conditions, including cancer and chronic inflammatory diseases, has named Anne Whitaker chief executive officer – effective 2 September 2014. Ms Whitaker will also become a member of the company's board of directors. She joins Lexington, Massachusetts-based Synta from Sanofi, where most recently she was president of its North American pharmaceuticals unit.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.